Background
==========

Artemisinin-based combination therapy (ACT) has been the mainstay treatment for *Plasmodium falciparum*malaria in Southeast Asia for more than 10 years and is now recommended as the first-line treatment throughout the world \[[@B1]\]. Artemisinins produce rapid therapeutic response, reduce gametocyte carriage, and are well tolerated by patients \[[@B2]\]. The World Health Organization (WHO) also recommends the use of artemisinin derivatives only in combination with effective partner drugs to ensure high cure rates and delay resistance. The five formulations of ACT recommended by WHO are artemether + lumefantrine, artesunate + mefloquine, artesunate + amodiaquine, artesunate + sulphadoxine-pyrimethamine and dihydroartemisinin + piperaquine \[[@B3]\].

In India, the national treatment policy prior to 2008 recommended chloroquine for *P. falciparum*and *P. vivax*treatment in areas where therapeutic studies had not been conducted or where treatment failure was less than 10%. However, systematic analyses of chloroquine resistance suggested the phenomenon was widespread \[[@B2],[@B4]\], not focal, and ACT was introduced by the National Vector Borne Disease Control Programme (NVBDCP) as the first-line treatment of falciparum malaria in 117 districts which represented more than 90% of the reported *P. falciparum*cases \[[@B5]\]. Presently all formulations of ACT recommended by WHO, except dihydroartemisinin + piperaquine, are registered with the Drug Controller General of India. In the public sector health system only artesunate + sulphadoxine-pyrimethamine blister packs were recommended though the combination was supplied as loose tablets as well.

The success of a new treatment policy depends on the adherence of health providers to the guideline and the compliance of patients with the recommended treatment. Equally, information on current provider and patient practices is needed to inform and improve future treatment policy. Recent reports note changes in pattern of drug prescription and utilization in public and private health facilities following changes in national treatment policy \[[@B6],[@B7]\]. However, inappropriate treatment practices continue in spite of the availability of evidenced-based guidelines \[[@B8]\]. Informal assessments and earlier studies in the Indian public and private sector suggest a substantial burden of incorrect treatments and an irrational use of antibiotics and injectables \[[@B9]\]. Large-scale evaluations of the state of anti-malarial treatment patterns, including the prescription of artemisinin monotherapy, were not available in India. Therefore, the treatment practices of physicians, patient experiences, and anti-malarial drug availability in pharmacies were evaluated in multiple sites across the country.

Methods
=======

Study areas
-----------

Six states were selected: Assam, Delhi, Goa, Gujarat, Jharkhand, and Orissa. Out of these, Assam, Jharkhand, and Orissa were priority states for *P. falciparum*control representing 55.1% of the reported burden in the country \[[@B5]\]. The other three states represented different transmission settings to provide a more representative national picture. In Goa, most malaria is associated with high-risk labour migration, while Gujarat is a low transmission setting with both major malaria species, and in Delhi local transmission is of *P. vivax*only. In each state, except Delhi, two districts (third level administrative unit of one to three million population) were selected based on the proportion of *P. falciparum*among all malaria (≥50%) in the district from surveillance data and the introduction of ACT by NVBDCP.

Study design
------------

A cross-section of conveniently selected health facilities in each site were surveyed during August to November 2008. Different levels of health facilities including district hospitals, primary health centres (PHC), subcentres, and private hospitals or clinics were interviewed. All physicians present in the selected health facility were interviewed. Surveys were also conducted amongst all pharmacists around a 5 km radius of selected health facilities. Finally, exit interviews were conducted in all patients leaving the selected health facility that day with either a diagnosis (clinical or laboratory) of malaria or to whom anti-malarial medicines were prescribed. An earlier study in Jharkhand described 17% artemisinin monotherapy (Mishra *et al*., unpublished data) among treatments. With 90% power and an alpha of 0.05, at least 1, 733 patients would be needed to detect a 20% prevalence in such a setting.

Data collection
---------------

Each interview team included one experienced surveyor and a trained supporting staff. Data was collected using pre-structured and pre-tested questionnaires. Physicians were interviewed about their years of experience in providing health services, educational qualifications, use of blood slide or rapid diagnostic kit (RDK) for diagnosis, and the prescription and frequency of use of different anti-malarials. Patients were interviewed about their symptoms, the diagnostic workup received along with its result, and drugs prescribed (if any). In the case of minor children, guardians/parents were interviewed. Paper records of the visit, tests, and prescription were also examined, if available. Pharmacists were interviewed and asked about the availability and sale of all anti-malarials in their stock.

Data analysis
-------------

A single data entry staff recorded results using Microsoft Excel 2003 and each entry was cross-checked by a senior investigator. Range checks were used to detect implausible values. Data analysis was conducted with STATA v10. Questionnaire responses were summated, physician characteristics were compared by public and private sector status, and diagnostic and treatment indicators were compared by state. Logistic regression was used to determine adjusted odds ratios for facility and clinical factors associated with artemisinin monotherapy. All univariate variables were included in the multivariable model except in the case of collinear predictors where the model with the better fit (lower AIC criterion) was retained.

Ethics
------

Verbal consent was obtained from all interviewees, data was de-identified, and the Scientific Advisory Committee of the National Institute of Malaria Research approved the study design and questionnaires. The study was a public health program evaluation conducted at the request of NVBDCP and thus IRB exempt.

Results
=======

Five hundred and eleven physicians and 1, 832 patients were interviewed in 98 private and 98 public sector health facilities (Table [1](#T1){ref-type="table"}) along with 530 pharmacists. No physician, patient, or pharmacists declined an interview. Public sector physicians had fewer years of clinical experience on average but a higher proportion of them had post-graduate training in medicine compared to physicians in the private sector. A high proportion of private sector physicians were non-allopathic trained.

###### 

Characteristics of 511 interviewed physicians by sector, India, 2008

                                   Public   Private   Total                   
  -------------------------------- -------- --------- ------- ------- ------- -------
  **Characteristic**               **n**    **%**     **n**   **%**   **n**   **%**
                                                                              
  *State*                                                                     
                                                                              
  Assam                            75       24.6      33      16.0    108     21.1
                                                                              
  Goa                              46       15.1      20      9.7     66      12.9
                                                                              
  Gujarat                          47       15.4      45      21.8    92      18.0
                                                                              
  Delhi                            44       14.4      28      13.6    72      14.1
                                                                              
  Jharkhand                        55       18.0      50      24.3    105     20.6
                                                                              
  Orissa                           38       12.5      30      14.6    68      13.3
                                                                              
  *Facility type*                                                             
                                                                              
  District hospital/nursing home   176      58.1      124     60.5    300     58.8
                                                                              
  PHC, subcentre/clinic            101      33.3      46      22.4    147     28.8
                                                                              
  Other                            28       9.2       35      17.1    63      12.4
                                                                              
  *Experience (years)*                                                        
                                                                              
  \< 2                             39       12.9      11      5.4     50      9.8
                                                                              
  2-10                             94       31.0      56      27.3    150     29.5
                                                                              
  10-20                            94       31.0      66      32.2    160     31.5
                                                                              
  \> 20                            76       25.1      72      35.1    148     29.1
                                                                              
  *Education*                                                                 
                                                                              
  MBBS                             131      43.0      74      35.9    205     40.1
                                                                              
  Post-graduate                    149      48.9      81      39.3    230     45.0
                                                                              
  Non-allopathic                   25       8.2       51      24.8    76      14.9

Missing: facility type (1), experience (3)

Case management practices by physicians for uncomplicated malaria
-----------------------------------------------------------------

Most physicians (62.2%) reported using both slides and RDKs for diagnosis. A higher proportion of private sector physicians used RDKs exclusively (9.2%) compared to those in the public sector (1.6%). Private sector physicians \'always\' prescribed more artemisinins alone, artemisinin plus other anti-malarials, and less artesunate + sulphadoxine-pyrimethamine (18.5%, 7.8%, 10.2% of prescriptions respectively) versus those in the public sector (6.9%, 3.6%, 14.1%) (Table [2](#T2){ref-type="table"}). Chloroquine was the most frequently prescribed anti-malarial drug in both sectors. Statewise \'always\' prescription of artesunate alone and of artesunate + sulphadoxine-pyrimethamine was highest in Jharkhand and Orissa, and Goa and Orissa respectively (Table [2](#T2){ref-type="table"}).

###### 

Prescribing frequency (%) of different anti-malarials by 511 interviewed physicians by sector or state, India, 2008

                  Public       Private                                                                                          
  --------------- ------------ ----------- ---------- ------------ ----------- ------------ ----------- ---------- ------------ -----------
  **Treatment**   **Always**   **Often**   **Some**   **Rarely**   **Never**   **Always**   **Often**   **Some**   **Rarely**   **Never**
                                                                                                                                
  Chloroquine     63.6         18.0        6.6        4.3          7.2         57.3         7.3         14.1       3.9          17.5
                                                                                                                                
  SP              1.6          5.6         13.4       10.8         68.2        2.9          10.7        6.8        11.2         68.5
                                                                                                                                
  Mefloquine      1.0          1.6         7.2        9.2          80.7        1.5          1.5         6.8        5.8          84.5
                                                                                                                                
  Quinine         7.2          22.6        23.3       11.8         34.8        10.7         16.5        15.5       17.5         39.8
                                                                                                                                
  ASP             14.1         11.2        20.0       8.5          45.9        10.2         12.1        10.2       5.8          61.7
                                                                                                                                
  As alone        6.9          20.0        23.3       12.5         37.1        18.5         20.9        16.0       12.1         32.5
                                                                                                                                
  As+other        3.6          4.9         10.8       7.2          73.1        7.8          3.9         4.9        4.9          78.6
                                                                                                                                
                  Assam        Goa                                                                                              
                                                                                                                                
  Chloroquine     65.7         14.8        9.3        2.8          7.4         87.9         6.1         1.5        0.0          3.0
                                                                                                                                
  SP              0.9          6.5         15.7       18.5         58.3        3.0          1.5         4.6        9.1          80.3
                                                                                                                                
  Mefloquine      0.0          0.0         3.7        7.4          88.9        4.6          3.0         6.1        12.1         72.7
                                                                                                                                
  Quinine         10.2         29.6        29.6       17.6         13.0        6.1          1.5         16.7       22.7         51.5
                                                                                                                                
  ASP             4.6          12.0        21.3       8.3          53.7        47.0         12.1        12.1       9.1          18.2
                                                                                                                                
  As alone        6.5          18.5        27.8       11.1         36.1        9.1          4.6         4.6        3.0          77.3
                                                                                                                                
  As+other        4.6          0.9         1.9        0.9          90.7        13.6         0.0         1.5        3.0          78.8
                                                                                                                                
                  Gujarat      Delhi                                                                                            
                                                                                                                                
  Chloroquine     79.4         2.2         1.1        1.1          16.3        55.6         34.7        1.4        0.0          8.3
                                                                                                                                
  SP              1.1          5.4         6.5        1.1          85.9        2.8          15.3        18.1       12.5         51.4
                                                                                                                                
  Mefloquine      0.0          1.1         1.1        1.1          96.7        2.8          2.8         23.6       8.3          62.5
                                                                                                                                
  Quinine         5.4          10.9        10.9       8.7          64.1        2.8          16.7        18.1       9.7          52.8
                                                                                                                                
  ASP             1.1          2.2         5.4        1.1          90.2        1.4          5.6         20.8       11.1         61.1
                                                                                                                                
  As alone        13.0         15.2        22.8       15.2         33.7        8.3          19.4        11.1       18.1         43.1
                                                                                                                                
  As+other        14.1         2.2         1.1        1.1          81.5        1.4          4.2         1.4        2.8          90.3
                                                                                                                                
                  Jharkhand    Orissa                                                                                           
                                                                                                                                
  Chloroquine     47.6         10.5        15.2       9.5          17.1        29.4         17.7        29.4       10.3         13.2
                                                                                                                                
  SP              3.8          12.4        8.6        11.4         63.8        1.5          2.9         10.3       11.8         73.5
                                                                                                                                
  Mefloquine      1.0          1.0         8.6        12.4         77.1        0.0          2.9         1.5        5.9          89.7
                                                                                                                                
  Quinine         13.3         31.4        16.2       9.5          29.5        11.8         22.1        29.4       19.1         17.7
                                                                                                                                
  ASP             6.7          14.3        14.3       10.5         54.3        27.9         25.0        23.5       4.4          19.1
                                                                                                                                
  As alone        15.2         30.5        28.6       15.2         10.5        17.7         30.9        17.7       8.8          25.0
                                                                                                                                
  As+other        1.9          1.0         1.9        3.8          91.4        7.4          0.0         0.0        0.0          92.7

305 public (1 missing) and 206 private physicians, As - artemisinin, As alone - artemisinin monotherapy, SP - sulphadoxine-pyrimethamine, ASP - artesunate+SP

Anti-malarial treatments prescribed to patients
-----------------------------------------------

Exit interviews results show a wide range of anti-malarial groups and treatments, as well as primaquine and antibiotics, were prescribed to 93.8% of patients (Table [3](#T3){ref-type="table"}). There were fifteen different treatment regimens recorded and the majority of patients received non-artemisinin monotherapy for the treatment of suspected or confirmed malaria. Artemisinin monotherapy represented 14.8% of the total prescriptions while recommended ACT represented 4.9% and other artemisinin combinations were 5.6% of the total. Overall, the co-prescription of primaquine was 34% reaching 87% among confirmed *P. vivax*patients in the public sector and 52% in private health facilities. The co-administration of antibiotics, 13.6% overall, was highest with chloroquine (n = 74) followed by patients without anti-malarial prescription (n = 23).

###### 

Anti-malarial groups and treatments prescribed to patients as well as primaquine and antibiotics from exit interviews, India, 2008

  Drug group/treatment          n        \%     PQ    Abx
  ----------------------------- -------- ------ ----- -----
  Artemisinin monotherapy       271      14.8   6     75
                                                      
                                                      
                                                      
  Non-artemisinin monotherapy   1, 241   68.0   520   98
                                                      
  Chloroquine                   1155            520   74
                                                      
  Primaquine                    5                     
                                                      
  Quinine                       74                    24
                                                      
  SP                            7                     
                                                      
                                                      
                                                      
  WHO ACT                       89       4.9    37    2
                                                      
  ASP blister                   30                    2
                                                      
  ASP loose                     16              5     
                                                      
  ASP+CQ                        37              31    
                                                      
  ASP+Q                         3               1     
                                                      
  ASP+CQ+Q                      3                     
                                                      
                                                      
                                                      
  Non-WHO ACT                   102      5.6    8     35
                                                      
  As+CQ                         63              7     19
                                                      
  As+Q                          37                    15
                                                      
  As+CQ+Q                       2               1     1
                                                      
                                                      
                                                      
  Non-artemisinin combination   15       0.8    7     0
                                                      
  CQ+SP                         13              7     
                                                      
  CQ+Q                          2                     
                                                      
                                                      
                                                      
  No anti-malarial drug         108      5.9    0     23
                                                      
  Missing                       6                     
                                                      
                                1832            583   233

CQ - chloroquine, SP - sulphadoxine-pyrimethamine, Q - quinine, As - artemisinin derivative, ASP - artesunate+SP, PQ - primaquine, Abx - antibiotic

Patient experiences of physician case management
------------------------------------------------

1, 600 patients in public and 232 patients in private health facilities were interviewed. Of these, 91% received some blood test with microscopy as the main diagnostic test (73.5%), followed by RDK (18.5%), and 7.3% were tested with both RDK and microscopy together (Figure [1](#F1){ref-type="fig"}). The use of artesunate monotherapy was 29.8% among confirmed *P. falciparum*patients, 5.5% for *P. vivax*, 2.7% for those with unknown diagnosis, 6.6% in those with negative reports, and 25.7% in patients with clinical assessment alone (Figure [1](#F1){ref-type="fig"}). Rational treatment, i.e. a non-anti-malarial prescription, was higher in smear negative patients (16.2%) compared to those who were tested using RDK or both (9.8%). The proportion of clinically diagnosed patients, those receiving artemisinin monotherapy, confirmed *P. falciparum*among total confirmed as well as the proportion of the former diagnosed by RDK were all highest in Jharkhand (Figure [2](#F2){ref-type="fig"}). Notably, 78% of confirmed *P. falciparum*patients in Goa received ACT (artesunate + sulphadoxine-pyrimethamine). Patients who were prescribed artemisinin monotherapy versus other regimens were compared by facility, patient, and management risks (Table [4](#T4){ref-type="table"}). The prescription of artemisinin monotherapy was higher in hospitals, patients 15 years or older, government health facilities, cases screened by RDK, and in *P. falciparum*confirmed patients. Adjusting for multiple risks, patients in Delhi and Jharkhand, exiting private health facilities, 15 years or older, and with mixed or confirmed *P. falciparum*infections had higher odds for receiving an artemisinin monotherapy prescription (Table [4](#T4){ref-type="table"}).

![**Flow chart of patient case management from exit interviews, India, 2008**. NA - non-artsesunate treatment, AM - artesunate monotherapy, ACT - WHO or non-WHO ACT, NM - non-antimalarial.](1475-2875-10-360-1){#F1}

![**State wise treatment (top) and diagnosis (bottom) trends from patient interviews, India, 2008**. Treatment legend (top): AM - artesunate monotherapy, PF w/ACT - Diagnosed *P. falciparum*cases prescribed WHO ACT, PV w/PQ - Diagnosed *P. vivax*cases prescribed primaquine. Diagnosis legend (bottom): Not tested - patients who did not receive a blood test, PF% - proportion of *P. falciparum*and mixed infection among diagnosed cases, PF w/RDK - *P. falciparum*cases diagnosed by RDK.](1475-2875-10-360-2){#F2}

###### 

Unadjusted and adjusted site, facility, patient, and management risks for artemisinin monotherapy (n = 273), India, 2008

                                                  Unadjusted   Adjusted             
  ------------------ -------- ----------- ------- ------------ ----------- -------- -----------
                     **AM**   **Other**   **%**   **OR**       **95%CI**   **OR**   **95%CI**
                                                                                    
  *State*                                                                           
                                                                                    
  Assam              9        296         3.0     \--                      \--      
                                                                                    
  Goa                1        217         0.5     0.2          0.0, 1.2    0.0      0.0, 0.4
                                                                                    
  Gujarat            24       197         10.9    4.0          1.8, 8.9    0.9      0.3, 2.8
                                                                                    
  Delhi              24       293         7.6     2.7          1.2, 5.9    5.4      1.7, 18
                                                                                    
  Jharkhand          185      266         41.0    23           11, 49      5.5      2.1, 15
                                                                                    
  Orissa             30       285         9.5     3.5          1.6, 7.5    0.3      0.1, 1.1
                                                                                    
  *Facility type*                                                                   
                                                                                    
  Hospital           240      1, 139      17.4    \--                      \--      
                                                                                    
  Primary clinic     33       415         7.4     0.4          0.3, 0.6    0.6      0.3, 1.1
                                                                                    
  *Age*                                                                             
                                                                                    
  \< 15 yrs          63       444         12.4    \--                      \--      
                                                                                    
  ≥15 yrs            209      1105        15.9    1.3          1.0, 1.8    1.8      1.2, 2.9
                                                                                    
  *Sex*                                                                             
                                                                                    
  Male               150      957         13.6    \--                      \--      
                                                                                    
  Female             123      597         17.1    1.3          1.0, 1.7    0.8      0.6, 1.3
                                                                                    
  *Sector*                                                                          
                                                                                    
  Government         241      1357        15.1    \--                      \--      
                                                                                    
  Private            32       197         14.0    0.9          0.6, 1.4    8.0      3.8, 17
                                                                                    
  *Diagnosis*                                                                       
                                                                                    
  Blood Slide        97       1, 122      8.0     \--                      \--      
                                                                                    
  RDK                119      190         38.5    7.2          5.2, 10     1.5      0.9, 2.7
                                                                                    
  Both               22       100         18.0    2.5          1.5, 4.2    1.8      0.9, 3.7
                                                                                    
  None               35       129         21.3    2.9          1.9, 4.4             
                                                                                    
  *Result*                                                                          
                                                                                    
  Malaria positive   194      621         23.8    \--                               
                                                                                    
  Malaria negative   36       503         6.7     0.2          0.2, 0.3             
                                                                                    
  Unknown            8        298         2.6     0.1          0.0, 0.2             
                                                                                    
  *Species*                                                                         
                                                                                    
  *P. vivax*         18       306         5.6     \--                      \--      
                                                                                    
  *P. falciparum*    166      305         35.2    9.3          5.4, 16     4.2      2.2, 7.8
                                                                                    
  Mixed infection    4        6           40.0    11           2.8, 46     5.0      0.9, 28

Missing: diagnosis type unknown (10), species (10), treatment (5), result and no diagnosis were dropped from adjusted analysis due to colinearity with other variables, AM - artemisinin monotherapy

Anti-malarial availability and sale in the pharmacy shop
--------------------------------------------------------

Among 530 pharmacy shops, 72.6% reported the sale of artemisinin derivatives alone in the past year. Of these, 44.2% of sales were injectable derivatives. The most common drug sold across the counter was chloroquine. Goa and Delhi had the high unavailability of artemisinin (46.3%, 55.6%) while the highest proportion of shops having sold injectable artemisinin derivatives were in Assam and Jharkhand (71.3%, 66.1%).

Discussion
==========

Artemisisin monotherapy was widely available in Indian pharmacies and frequently prescribed by according to both patient and physician interviews. Overall case management varied between the public and private sector as well as region.

Artemisinin monotherapy
-----------------------

The inappropriate use of anti-malarials in the past has contributed to decreased drug sensitivities today \[[@B10]\]. Recent therapeutic efficacy studies along the Thai-Cambodia border described an increased proportion of patients who were parasitaemic on the third day of follow-up, indicating reduced parasite susceptibility to artemisinins in an area where oral artemisinin monotherapies were widely available \[[@B11]\]. In this study, the easy accessibility, unregulated sale of oral artemisinin monotherapy in the retail market, and inadequate availability of the recommended ACT in public and private health facilities were key contributors. In informal discussions with physicians, other factors hindering the implementation of the new policy were the inertia of practitioners in accepting new treatments, lack of awareness about the new drug policy, and fear of stock outs. The widespread availability of artemisinin monotherapy in both oral and injectable forms, and the different policies surrounding each, also caused prescription confusion. Notably, monotherapy use was strongly associated with private sector care in multivariable analysis where a higher proportion of physicians were non-allopathic. Unsurprisingly, monotherapy use was higher in both *P. falciparum*patients and *P. falciparum*areas. After that however, use was highest among patients who did not receive a blood test and were treated clinically. Dodoo *et al*. reported similar results from Ghana where the prescription of artesunate monotherapy was highest in blood smear positive patients (32.9%) followed by patients without blood tests (21%), underscoring the need for discouraging presumptive treatment \[[@B12]\].

Rational case management
------------------------

Proper case management, guided by a laboratory diagnosis, reduces the overconsumption of all anti-malarials, including artemisinin monotherapy. Presumptive treatment in India is discouraged and over 90% of patients in both sectors received a blood test and only a small proportion of patients testing negative or unknown received artemisinin monotherapy. However, many smear or RDK negative patients still received another anti-malarial suggesting a lack of confidence in the diagnosis and/or a lack of concern about the overuse of anti-malarials. In the case of patients tested with RDK alone and microscopy is not available, treatment for vivax malaria may be reasonable as all kits in the public sector were monovalent and detect *P. falciparum*alone. Radical treatment, anti-relapse therapy for *P. vivax*or anti-gametocidal therapy for *P. falciparum*, using primaquine is also an important goal for control. At the time of the study no guidelines for the use of primaquine with ACT in uncomplicated *P. falciparum*malaria were available. For confirmed vivax malaria most patients seen in the public sector received a prescription for primaquine but only half of those in the private sector did. Whether the dose and duration of treatment, as well as counselling for side-effects, were appropriate is unknown. Finally, the co-administration of antibiotics in uncomplicated malaria cases was frequent and is a cause for concern.

Scaling Up ACT
--------------

This study was conducted in 2008 about 1 year after ACT became the recommended treatment of *P. falciparum*cases in limited areas: demonstrated chloroquine resistance, malaria deaths, high proportion of *P. falciparum*. A total of 117 districts were eligible and represented the majority of the reported falciparum malaria burden of the country. ACT blister packs were deployed through NVBDCP for 15 years or older age groups and efforts to produce blister packs for other age groups were ongoing. In this study all of the sampled districts were targeted for ACT except for Delhi. However, the use of ACT for confirmed *P. falciparum*cases was low with the exception of Goa. International attention has focused on identifying sustainable resources for purchasing the needed drugs for widespread deployment through public sector health systems \[[@B13]\]. In India, this is less of a concern where substantial funding was available through the central government. The effective implementation of ACT needs active participation at all levels including members from the periphery health services due to the complex federal structure of the nation and its large size and population. Supply chain improvement and training to dispense the correct dose of ACT is required, particularly to paramedical health workers whose literacy is nominal. The current product profile of ACT used in the country also requires improvement to simplify prescription and promote higher adherence to treatment. They were available exclusively as co-blistered products for adults (\> 15 years of age; artesunate in combination with sulphadoxine-pyrimethamine). Lack of availability of different age-specific courses of therapy and short shelf-life (2 years) were other limitations.

Limitations
-----------

This study was conducted in 2008 relatively soon after the first widespread introduction of ACT in country. Even blister packs for different age groups were unavailable necessitating supply of loose tablets of artesunate to be made available in the PHC which may have increased monotherapy use. As the study was conducted for public health needs, important areas were purposively selected rather than random sites and the results may not be population representative. Physician and pharmacist responses may have been biased to appear desirable, however, confidentiality was stressed and participation was 100%.

Conclusions
===========

Following this study, strict regulation on industry as well as retail outlets was imposed by the Drug Controller General of India leading to a total ban on the sale of oral artemisinin monotherapy since July 2009. Creating awareness among health providers to change clinical practices remains the greatest challenge, particularly in the large private sector. Fixed dose combinations, which prevent the accidental or intentional use of artemisinin monotherapy, are the best available option for future policy. Ensuring access to effective ACT in both public and private sectors, while progressively removing oral artemisinin monotherapies from the market, is essential to provide effective treatment and prevent the development of artemisinin resistance.
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